An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin-/- mice and patients

Neurobiology of Disease

Volumn 30, Issue 1, 2008, Pages 74-83

  Lin, Jian Sheng ^a,b   Dauvilliers, Yves ^c   Arnulf, Isabelle ^d   Bastuji, Hélène ^e   Anaclet, Christelle ^a,b   Parmentier, Régis ^a,b   Kocher, Laurence ^f   Yanagisawa, Masashi ^g   Lehert, Philippe ^h   Ligneau, Xavier ⁱ   Perrin, David ⁱ   Robert, Philippe ⁱ   Roux, Michel ^j   Lecomte, Jeanne Marie ^j   Schwartz, Jean Charles ^i,j  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c GUI DE CHAULIAC HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔPITAL NEUROLOGIQUE   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h FUCAM   (Belgium)

ⁱ Bioprojet Biotech ^*  (France)

^j Laboratoire Bioprojet   (France)

more..

Author keywords

H3 receptor inverse agonist; Histamine; Narcolepsy; Orexin; Sleep disorders; Somnolence; Wakefulness

Indexed keywords

HISTAMINE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; MODAFINIL; MODIONAL; OREXIN; PLACEBO; TIPROLISANT; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; ARTICLE; AUDITORY HALLUCINATION; CATAPLEXY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DRUG DOSE REDUCTION; DRUG EFFECT; EPWORTH SLEEPINESS SCALE; FEMALE; HEADACHE; HISTAMINE RELEASE; HUMAN; INSOMNIA; MALAISE; MALE; MORNING DOSAGE; MOUSE; MULTICENTER STUDY; NARCOLEPSY; NAUSEA; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REM SLEEP; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; SWEATING; WAKEFULNESS;

ANIMALS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; FEMALE; HISTAMINE AGONISTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NARCOLEPSY; NEUROPEPTIDES; PIPERIDINES; POLYSOMNOGRAPHY; PROSPECTIVE STUDIES; REACTION TIME; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SLEEP STAGES; WAKEFULNESS;

EID: 40849137722     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.12.003     Document Type: Article

References (46)

1. 3 receptors. Nature 327 (1987) 117-123
2. Baumann C.R., and Bassetti C.L. Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter. Sleep Med. Rev. 9 (2005) 253-268
3. Bayer L., Eggermann E., Serafin M., Saint-Mleux B., Machard D., Jones B., and Muhlethaler M. Orexins (hypocretins) directly excite tuberomammillary neurons. Eur. J. Neurosci. 14 (2001) 1571-1575
4. Billiard M., Bassetti C., Dauvilliers Y., Dolenc-Groselj L., Lammers G.J., Mayer G., Pollmacher T., Reading P., and Sonka K. EFNS guidelines on management of narcolepsy. Eur. J. Neurol. 13 (2006) 1035-1048
5. Black J., and Houghton W.C. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 29 (2006) 939-946
6. 3 receptor antagonists: from target identification to drug leads. Biochem. Pharmacol. 73 (2007) 1084-1096
7. Bourgin P., Huitron-Resendiz S., Spier A.D., Fabre V., Morte B., Criado J.R., Sutcliffe J.G., Henriksen S.J., and de Lecea L. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J. Neurosci. 20 (2000) 7760-7765
8. Bouthenet M.L., Ruat M., Sales N., Garbarg M., and Schwartz J.C. A detailed mapping of histamine H1-receptors in guinea-pig central nervous system established by autoradiography with [125I]iodobolpyramine. Neurosci. 26 (1988) 553-600
9. Brown R.E., Sergeeva O.A., Eriksson K.S., and Haas H.L. Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). J. Neurosci. 22 (2002) 8850-8859
10. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., Fitch T.E., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98 (1999) 437-451
11. Dauvilliers Y., Arnulf I., and Mignot E. Narcolepsy with cataplexy. Lancet 369 (2007) 499-511
12. Eriksson K.S., Sergeeva O., Brown R.E., and Haas H.L. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J. Neurosci. 21 (2001) 9273-9279
13. Ferraro L., Tanganelli S., O'Connor W.T., Antonelli T., Rambert F., and Fuxe K. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci. Lett. 220 (1996) 5-8
14. Fujiki N., Cheng T., Yoshino F., and Nishino S. Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 narcoleptic mice. Sleep 29 (2006) A225 (Abstract Suppl)
15. Huang Z.L., Qu W.M., Li W.D., Mochizuki T., Eguchi N., Watanabe T., Urade Y., and Hayaishi O. Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9965-9970
16. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14 (1991) 540-545
17. Kish S.J., Mamelak M., Slimovitch C., Dixon L.M., Lewis A., Shannak K., DiStefano L., Chang L.J., and Hornykiewicz O. Brain neurotransmitter changes in human narcolepsy. Neurology 42 (1992) 229-334
18. Korotkova T.M., Sergeeva O.A., Ponomarenko A.A., and Haas H.L. Histamine excites noradrenergic neurons in locus coeruleus in rats. Neuropharmacol 49 (2005) 129-134
19. 3-receptor inverse agonists studied with BF2.649. Biochem. Pharmacol. 73 (2007) 1215-1224
20. 3 receptor: preclinical pharmacology. J. Pharmacol. Exp. Ther. 320 (2007) 365-375
21. 3-receptor antagonist. J. Pharmacol. Exp. Ther. 287 (1998) 658-666
22. Lin J.S. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med. Rev. 4 (2000) 471-503
23. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., Qiu X., Nishino S., and Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (1999) 365-376
24. Lin J.S., Roussel B., Akaoka H., Fort P., Debilly G., and Jouvet M. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res. 591 (1992) 319-326
25. Mignot E. Narcolepsy: pharmacology, pathophysiology and genetics. In: Kryger M.H., Roth T., and Dement W.C. (Eds). Principles and Practice of Sleep Medicine. 4th edition (2005), Elsevier Saunders, Philadelphia 761-779
26. Mignot E., and Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 28 (2005) 754-763
27. 3 receptors regulates histamine neurons in brain. Nature 408 (2000) 860-864
28. Nishino S., Fujiki N., Ripley B., Sakurai E., Kato M., Watanabe T., Mignot E., and Yanai K. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci. Lett. 313 (2001) 125-128
29. Nishino S., Ripley B., Overeem S., Lammers G.J., and Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355 (2000) 39-40
30. 3 receptor as novel therapeutic target for vigilance and sleep-wake disorders. Biochem. Pharmacol. 73 (2007) 1157-1171
31. Parmentier R., Ohtsu H., Djebbara-Hannas Z., Valatx J.L., Watanabe T., and Lin J.S. Anatomical, physiological and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioural and sleep-wake control. J. Neurosci. 22 (2002) 7695-7711
32. 3 receptor and its gene transcripts in rat brain. Neurosci 114 (2002) 173-193
33. Scammell T.E., Estabrooke I.V., McCarthy M.T., Chemelli R.M., Yanagisawa M., Miller M.S., and Saper C.B. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J. Neurosci. 20 (2000) 8620-8628
34. 3-receptor-mediated inhibition of noradrenaline release in the mouse brain cortex. Naunyn-Schmiedebergs Arch. Pharmacol. 345 (1992) 489-493
35. Schwartz J.C., Arrang J.M., Garbarg M., Pollard H., and Ruat M. Histaminergic transmission in the mammalian brain. Physiol. Rev. 71 (1991) 1-51
36. Sherin J.E., Elmquist J.K., Torrealba F., and Saper C.B. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J. Neurosci. 18 (1998) 4705-4721
37. Siegel J.M. Narcolepsy: a key role for hypocretins (orexins). Cell 98 (1999) 409-412
38. Sutcliffe J.G., and de Lecea L. The hypocretins: setting the arousal threshold. Nat. Rev. Neurosci. 3 (2002) 339-349
39. Takahashi K., Lin J.S., and Sakai K. Neuronal activity of histaminergic tuberomammillary neurons during wake-sleep states in the mouse. J. Neurosci. 26 (2006) 10292-10298
40. Tanganelli S., Mora M.P., Ferraro L., Mendez-Franco J., Beani L., Rambert F., and Fuxe K. Modafinil and cortical Υ{hooked}-aminobutyric outflow. Modulation by 5-hydroxytryptamine neurotoxins. Eur. J. Pharmacol. 273 (1995) 63-71
41. The International Classification of Sleep Disorders. Diagnostic and coding manual. American Academy of Sleep Medicine. 2nd ed. (2005), Chicago
42. Valatx J.L. Enregistrement chronique des activités électriques cérébrales, musculaires et oculaires chez la souris. CR Séances Soc Bio. Fil. 165 (1971) 112-115
43. Valatx J.L., and Bugat R. Facteurs génétiques dans le déterminisme du cycle veille-sommeil chez la souris. Brain Res. 69 (1974) 315-330
44. 3-receptor ligands: an electrophysiological study in freely moving cats. Behav. Brain Res. 144 (2003) 227-241
45. Wisor J.P., and Eriksson K.S. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neurosci 132 (2005) 1027-1034
46. Wu M.F., Gulyani S.A., Yau E., Mignot E., Phan B., and Siegel J.M. Locus coeruleus neurons: cessation of activity during cataplexy. Neurosci 91 (1999) 1389-1399